INO · Inovio Pharmaceuticals, Inc. · Proposed Sales
$1.16
+0.03 (+2.21%)
At close · Oct 7
View the 10-K filed Mar 12, 2026
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We do not currently have sufficient working capital to fund our planned operations for the next twelve months and substantial doubt exists as to our ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Customer concentration
— key customers 100% of revenue
Key customers — 100% of revenue (the years ended December 31, 2025 and 2024)
“During the years ended December 31, 2025 and 2024, we derived 100% of our revenue from ApolloBio.”
Market Cap
$119.42M
Shares
103.40M
Volume · Oct 7
2.8M
Avg daily vol (3M)
3.79M
Notices of intent to sell restricted or control shares, filed with the SEC on Form 144 by insiders and affiliates. A Form 144 signals a planned sale — it does not confirm the shares were actually sold.